Organoid technology has reshaped regenerative medicine by moving beyond flat cell culture toward self-organized three-dimensional microtissues that better reproduce native tissue architecture and function. Unlike conventional two-dimensional cultures, bone organoids preserve cell-cell communication, cell-matrix interactions, lineage patterning, and extracellular matrix remodeling within a spatially relevant environment. Recent years have seen skeletal organoid systems expand to include bone marrow-like, trabecular-like, callus-like, and woven-bone-like constructs, with matrix engineering and biofabrication enabling tighter control of geometry and maturation. Yet the field still confronts key barriers, including inadequate vascularization, immature mechanics, diffusion limitations in larger constructs, and the absence of standardized bioactive programming. In this study, the term bone organoids refers specifically to bone marrow stromal cell-derived three-dimensional osteogenic microtissues that reproduce selected features of bone formation, including cell-cell interaction, matrix production, and mineral deposition, rather than fully vascularized or marrow-containing bone equivalents.

Achyranthes bidentata, the botanical source of a traditional Chinese medicine, emerged as an attractive candidate for biofunctionalizing such constructs. Pharmacognostic studies identify multiple bioactive constituents in the plant, including polysaccharides, saponins, steroids, and related small molecules, and toxicology work suggests a favorable safety profile at therapeutic doses. Experimental evidence supports a direct role in skeletal repair: AB saponins promote osteogenic differentiation of bone marrow stromal cells through the ERK/MAPK pathway, osteoblast studies show enhanced proliferation and Runx2-associated osteogenic activity after treatment, and purified polysaccharide fractions exhibit in vitro osteogenic activity. In parallel, AB regulates the resorptive arm of bone remodeling, with prior studies demonstrating suppression of osteoclastogenesis through inhibition of RANKL signaling and osteoprotective effects in vivo through regulation of the RANKL/RANK/OPG axis. This dual anabolic and anti-resorptive potential is precisely the type of combined cue needed for functional bone regeneration, yet until now AB research and organoid engineering had largely progressed in parallel.

The research team, led by Chenxing Lu and colleagues, designed a four-stage workflow: dose screening of AB in rat bone marrow-derived mesenchymal stromal cells, generation and characterization of AB-bone organoids, evaluation in a critical-sized calvarial defect model, and an exploratory retrospective clinical analysis of AB exposure in tibial fracture healing. The botanical material was authenticated by macroscopic and microscopic examination according to the Pharmacopoeia of the People’s Republic of China, with voucher specimens deposited at the Institute of Chinese Materia Medica. Dried roots were decocted with distilled water, filtered, concentrated, and lyophilized to an 18.5 percent extraction yield, then characterized by high-performance liquid chromatography fingerprinting to establish batch traceability before any biological testing began.

Dose screening revealed a concentration-dependent osteopromotive window. Bone marrow stromal cells exposed to graded concentrations from 0 to 400 micrograms per milliliter showed good cytocompatibility at low and intermediate doses, with cell viability and proliferative activity rising steadily up to 200 micrograms per milliliter, the concentration that produced peak alkaline phosphatase activity and Alizarin Red S-detected mineralization. At 400 micrograms per milliliter, the proliferative benefit was attenuated, indicating that the effect was concentration dependent rather than linearly cumulative. Quantitative PCR confirmed that AB markedly upregulated the osteogenic program, increasing expression of Col1a1, Runx2, Opn, and Ocn. Mechanistic experiments using PD98059, a selective ERK/MAPK pathway inhibitor, showed that AB increased ERK1/2 phosphorylation and that blocking the pathway partially attenuated AB-enhanced alkaline phosphatase activity and mineralized matrix formation, implicating ERK/MAPK signaling as a partial, though not exclusive, contributor to the herb’s pro-osteogenic effect.

The pivotal step came when the team incorporated AB into bone organoid culture. Single-cell suspensions of stromal cells were seeded into ultra-low-attachment plates to form compact spheroids over three days, then embedded in growth factor-reduced Matrigel and cultured in osteogenic medium for 28 days, with 200 micrograms per milliliter AB added throughout maturation. Live/dead staining showed both groups remained viable, but AB-treated organoids displayed more widespread calcein-AM signal and reduced propidium iodide incorporation. Quantitative analysis demonstrated that AB-treated organoids achieved a larger cross-sectional area, suggesting accelerated tissue assembly and volumetric growth. Histological and matrix analyses confirmed the functional differences: AB-bone organoids exhibited stronger Alizarin Red S, alkaline phosphatase, and collagen type I staining, indicating enhanced calcium deposition, osteogenic enzyme activity, and extracellular matrix production, while immunofluorescence revealed more organized F-actin architecture and stronger Runx2 expression consistent with heightened osteogenic lineage activation.

Head-to-head comparison of monolayer cultures, untreated bone organoids, and AB-bone organoids revealed a stepwise enhancement in osteogenic output, with AB-bone organoids achieving the highest levels of enzymatic activity and matrix mineralization, accompanied by increased protein expression of COL-I, Runx2, and OPN and higher viability. The decisive test, however, came in vivo. In a critical-sized 5-millimeter calvarial defect model in adult rats, animals receiving AB-bone organoids showed more extensive defect bridging and denser mineralized tissue on micro-CT reconstructions at 12 weeks than those receiving untreated organoids or no implant. Quantitative analysis confirmed the most favorable bone microarchitecture in the AB-bone organoid group, with increased bone volume fraction, bone mineral density, trabecular thickness, and trabecular number, together with reduced trabecular separation. Histology showed greater bone fill and more organized collagen deposition, and immunohistochemistry revealed more abundant COL-I, OPN, and OCN-positive matrix within the regenerative area.

To explore clinical relevance, the team conducted a retrospective cohort study at Taizhou Hospital of Traditional Chinese Medicine, screening 126 consecutive tibial fracture patients operated on between January 2022 and December 2024, of whom 40 met eligibility criteria and were divided into 20 receiving oral AB beginning one month after surgery for six weeks and 20 receiving standard care. Baseline characteristics were well balanced between groups. Postoperative AB administration was associated with substantially shorter mean radiographic healing time of 3.8 versus 4.9 months, higher modified Radiographic Union Scale scores at final follow-up of 14.1 versus 12.3, lower pain scores of 1.3 versus 2.6 on the visual analogue scale, and superior lower-extremity function scores of 72.5 versus 65.2. Serial radiographs showed earlier callus formation and advanced remodeling in AB-treated patients, although the proportion achieving union by six months did not differ significantly.

The authors are careful to delineate the boundaries of these findings. The animal experiment evaluated localized implantation of AB-preconditioned organoids, while the clinical cohort evaluated systemic oral administration with entirely different pharmacokinetics, so the human data provide only indirect, hypothesis-generating support rather than evidence for the clinical feasibility of organoid implantation. Retrospective design cannot fully account for unmeasured confounding, and factors such as fracture severity, fixation characteristics, and rehabilitation compliance were not uniformly available. The calvarial model is non-load-bearing, vascularization was not directly quantified, the specific bioactive constituents responsible remain unidentified, and the ERK/MAPK experiments were conducted only in monolayer cells. Even so, the conceptual advance is considerable: a traditional osteoactive botanical factor has been repurposed as a developmental instruction for bone organoids, upgrading the therapeutic unit from isolated cells or soluble factors to an implantable living osteogenic microtissue, and defining a promising direction for biologically instructed bone regeneration that now awaits testing in load-bearing models, vascularized constructs, and eventually dedicated clinical trials.

Subject of Research: Achyranthes bidentata-functionalized bone marrow stromal cell-derived bone organoids for enhanced bone defect repair

Article Title: Achyranthes bidentata –functionalized bone organoids enhance bone defect repair

Article References: Lu, C., Qin, X., Lin, Z., Han, S., Ding, P., Xu, L., Zheng, X., Hu, B., Chen, F., & Wu, D. (2026). Achyranthes bidentata–functionalized bone organoids enhance bone defect repair. Materials Today Bio, 41, Article 103716. https://doi.org/10.1016/j.mtbio.2026.103716

Image Credits: AI Generated

DOI: 10.1016/j.mtbio.2026.103716

Keywords: bone organoids, Achyranthes bidentata, bone regeneration, critical-sized defects, mesenchymal stromal cells, ERK/MAPK signaling, traditional Chinese medicine, calvarial defect model, fracture healing, osteogenesis, tissue engineering, Materials Today Bio

The study, published in the International Journal of Legal Medicine, was led by Wen-tao Xia of the Academy of Forensic Science in Shanghai, together with co-first authors Ya-ning Sun and Lei Wan and their colleagues. Rather than building a system that performs a single narrow task, the team designed a multi-task learning model based on a three-dimensional residual neural network, known as 3D-ResNet18. A single network simultaneously performs three distinct jobs: it predicts the numerical age of a fracture in days, it classifies the fracture into its healing stage, and it identifies the type of fracture present. This architecture matters because the three tasks are deeply intertwined. The radiological signs that indicate a fresh fracture are the same biological processes that define its healing stage, and forcing the network to learn all three objectives at once encourages it to extract richer, more generalizable features from the image data than a single-purpose model could.

To train and validate the model, the researchers assembled a multicenter dataset of 1,848 rib fractures identified on chest CT scans. Multicenter data is a crucial ingredient in medical artificial intelligence because images acquired on different scanners, with different protocols and from different patient populations, vary in subtle ways. Models trained on data from a single hospital frequently fail when deployed elsewhere, a phenomenon that has undermined many promising AI tools. By drawing training examples from multiple sources and then testing the model on an external dataset it had never seen, the team directly addressed the generalizability question that separates laboratory demonstrations from clinically useful systems. The external test confirmed that the model’s performance held up beyond the institutions where it was developed.

The headline numbers are striking. In the fracture age prediction task, the model achieved a mean absolute error of 7.94 days, meaning that on average its estimate of how long ago a fracture occurred was off by less than eight days. In head-to-head comparison, human expert evaluation of the same fractures produced a mean absolute error of 10.65 days. The gap of more than two and a half days may sound modest, but in forensic contexts, where the difference between a fracture sustained during a documented incident and one sustained weeks earlier can determine the outcome of a case, that improvement carries real weight. For the healing stage classification task, the model reached an accuracy of 71.18 percent, and in the fracture type classification task it achieved 94.71 percent, a level of performance that approaches the reliability of specialized detection systems.

Underneath these results lies a biological story that the algorithm has effectively learned to read. When a rib breaks, the body initiates a predictable cascade of repair. In the earliest phase, hemorrhage and inflammation dominate, and the fracture line itself may be barely visible on CT. Over the following days and weeks, soft callus forms around the fracture ends, followed by hard, mineralized callus that gradually bridges the gap. Eventually the callus remodels, and the bone slowly returns toward its original architecture. Each of these stages leaves a distinct radiological signature: changes in fracture line sharpness, callus density and volume, and eventual bony union. Radiologists have long used these signs to make rough estimates of fracture age, but the transitions are gradual and their appearance varies with patient age, bone density, and health status. A convolutional neural network processing volumetric CT data can, in principle, detect patterns in these transitions that are too subtle or too distributed for consistent human recognition.

The choice of a 3D architecture is technically significant. Rib fractures are inherently three-dimensional injuries, and the diagnostic cues they present may span multiple consecutive CT slices. A two-dimensional network analyzing each slice in isolation would discard that spatial context. By feeding volumetric patches through a 3D residual network, the model can integrate information along the length of the rib and across the fracture site, capturing the full morphology of callus formation and fracture line evolution. The residual connections within ResNet18, a now-classic design that allows gradients to flow through very deep networks during training, help the model learn fine-grained image features without succumbing to the training instabilities that plagued earlier deep architectures. The study was implemented using MONAI, an open-source framework for medical deep learning, reflecting the growing standardization of tools in this field.

The forensic implications extend well beyond rib fractures alone. The cited literature surrounding this work paints a sobering picture of why objective fracture dating is needed. Radiologists have documented imaging patterns of thoracic injuries in survivors of intimate partner violence, and separate studies have examined the radiological appearance of physical elder abuse and nonaccidental injury in the elderly. Missed rib fractures on initial trauma CT scans are a recognized problem with both clinical and forensic consequences. In cases of suspected abuse, the timing of injuries is often central to the investigation: a fracture consistent with the account given by a caregiver supports one narrative, while a fracture that predates or postdates the reported incident undermines it. Prior research has even documented self-inflicted long bone fractures in insurance fraud cases, where dating an injury could expose deception. A reproducible, quantitative tool for fracture dating gives investigators and courts evidence that does not depend on which expert happened to review the scan.

The new model also builds on a clear trajectory of prior work. Earlier studies by some of the same research community demonstrated that convolutional neural networks could detect and classify rib fractures on CT with high accuracy, and a separate multicenter study showed that a radiomics-based combined model could estimate rib fracture age from CT scans. Work from other groups has applied deep learning to estimate time-since-injury in pediatric fractures, one of the most sensitive applications in forensic radiology. The present study advances this line of research by combining age regression, healing stage classification, and fracture type identification in a single multi-task framework, and by demonstrating that the combined model outperforms manual expert evaluation on the age estimation task in external testing.

Limitations and caveats remain, as they do for any medical AI system. The raw data could not be publicly shared because of participant privacy, ethical restrictions, and legal constraints, though the authors state that de-identified data are available upon reasonable request subject to ethics approval and a data use agreement. Fracture healing is known to vary with factors such as age and bone mineral density, and the model’s performance across the full spectrum of patient populations and healing conditions will require continued scrutiny as the tool moves toward practical use. The study protocol was approved by the Ethics Committee of the Academy of Forensic Science with a waiver of informed consent, and the work was supported by China’s National Key R&D Program and several national and Shanghai-level research grants.

Still, the direction of travel is unmistakable. Artificial intelligence systems have already proven themselves at detecting rib fractures, localizing them anatomically, and flagging injuries that tired human readers miss. With this study, the same technology now demonstrates that it can read the clock embedded in healing bone more precisely than the experts who trained the field. For emergency physicians triaging trauma patients, for forensic pathologists reconstructing the sequence of events in a death investigation, and for child protection teams weighing whether an injury matches the story they have been told, a day-level estimate of fracture age delivered automatically from an existing chest CT could become a routine part of the diagnostic workflow. The rib has always kept a record of when it was broken. What has changed is that a neural network can now read that record with a precision the human eye could never consistently achieve.

Subject of Research: Deep learning estimation of rib fracture age from chest CT for forensic medicine

Article Title: A multi-task learning–based deep learning model for precise estimation of rib fracture age on chest CT

Article References: Sun, Y.-N., Wan, L., Yu, X.-Y., Wang, M.-W., Zhu, K., Li, Y.-Z., Liu, T.-A., Sheng, Y.-L., & Xia, W.-T. (2026). A multi-task learning–based deep learning model for precise estimation of rib fracture age on chest CT. International Journal of Legal Medicine. https://doi.org/10.1007/s00414-026-03962-3

Image Credits: AI Generated

DOI: 10.1007/s00414-026-03962-3

Keywords: deep learning, rib fracture, forensic medicine, chest CT, fracture age estimation, multi-task learning, 3D-ResNet18, fracture healing, artificial intelligence, legal medicine, computer vision, trauma imaging

The central problem the researchers set out to solve is one of personalization. LIPUS has been studied for decades as a way to stimulate bone regeneration, and commercial devices based on the technology have existed for years, but the optimal stimulation parameters are not universal. The intensity of the acoustic waves, the fraction of time the ultrasound is actually switched on during each cycle, known as the duty cycle, and the duration of each session can all influence how effectively the mechanical energy translates into biological stimulation of cells. Different tissues and different clinical situations, from a fresh fracture to a stubborn non-union, may respond best to different settings. Yet most existing systems offer limited or no adjustability, and their cost places them beyond the reach of many hospitals, particularly in resource-limited settings.

The new platform operates at a frequency of 1.5 megahertz, a standard choice for therapeutic ultrasound that balances penetration depth with energy delivery to superficial and mid-depth tissues. What distinguishes the device is its configurability. Clinicians can set acoustic intensities ranging from 40 to 60 milliwatts per square centimeter, a range firmly within the low-intensity window associated with stimulatory rather than destructive effects on tissue. The duty cycle can be adapted across ratios from 1:1, meaning the transducer is active for half of each cycle, to 1:4, meaning it is active for one fifth of the time, allowing the delivered acoustic dose to be tuned to the biological context. Each treatment session lasts 30 minutes, a duration consistent with established LIPUS protocols. The system was designed to be portable and inexpensive, explicitly targeting outpatient departments and clinical environments where conventional, high-priced LIPUS units are impractical.

The clinical evaluation was structured around a retrospective controlled fracture cohort of 53 patients, of whom 31 received adjunctive LIPUS treatment alongside standard orthopedic care while 22 served as controls receiving standard care alone. Importantly, the cohort was not limited to straightforward recent fractures. It deliberately included patients with delayed unions, where healing has slowed beyond the expected timeline, and established non-unions, where the fracture has failed to unite altogether and revision surgery is often the only remaining option. This severity spectrum matters because it tests whether adaptive ultrasound stimulation can help in precisely the situations where conventional management struggles most.

The headline result concerns recent fractures. Patients treated with adjunctive LIPUS achieved healing in an average of 1.43 plus or minus 0.59 months, compared with 3.86 plus or minus 2.82 months in the control group, a difference the authors report as statistically significant with a p-value of 0.001. In practical terms, the treated group healed in roughly six weeks on average while untreated patients required nearly four months, with much greater variability in recovery time. To assess the robustness of this finding across the whole cohort, the researchers performed Kaplan-Meier survival analysis, a statistical technique borrowed from oncology that estimates the probability of an event over time. Here the event of interest was fracture union, and the analysis revealed a significantly faster probability of union in the LIPUS-treated group compared with controls, confirming that the benefit was not confined to a favorable subgroup but held across the cohort.

Equally notable were the outcomes in the more biologically complex cases. Delayed-union and non-union fractures, which often require surgical intervention such as bone grafting or internal fixation revision, demonstrated favorable healing outcomes under LIPUS treatment despite their increased biological complexity. Non-unions in particular represent a substantial clinical and economic burden, and any non-invasive therapy capable of rescuing these cases without surgery carries significant value. While the retrospective design and the modest sample size of this subgroup warrant caution, the pattern of results supports the idea that adjustable stimulation parameters, tuned to fracture severity, can extend the usefulness of ultrasound therapy to patients who currently have few options short of the operating room.

Beyond bone, the team explored an application that has received far less systematic attention: chronic tendinopathic disorders. An exploratory cohort of 27 patients was treated, comprising 12 individuals with chronic lateral epicondylitis, the degenerative tendon condition commonly known as tennis elbow, and 15 with Achilles tendinopathy. These patients were not fresh cases; they had prolonged symptom duration and had already failed previous conservative treatment, meaning they represented exactly the kind of chronic, recalcitrant population for which effective non-surgical options are scarce. Tendons, with their poor blood supply and slow cellular turnover, are notoriously difficult to regenerate, and the prospect of using mechanical stimulation to nudge tenocytes toward repair has long interested researchers.

The results in this tendon cohort were striking. Overall, 92.6 percent of patients exceeded a predefined clinically meaningful improvement threshold of 75 percent, despite their long-standing symptoms and prior treatment failures. A threshold defined in this way is more demanding than simply reporting statistical improvement on a symptom score; it asks whether patients experienced a change large enough to matter in daily life. That more than nine in ten patients crossed it, in an exploratory uncontrolled cohort, suggests that adaptive LIPUS deserves rigorous prospective evaluation in tendinopathy, potentially offering a non-invasive alternative to corticosteroid injections, which can weaken tendon tissue, or to surgery, which carries its own risks and rehabilitation burden.

The engineering philosophy behind the device is as significant as the clinical numbers. The authors emphasize that the platform is portable and low-cost, designed from the outset for translational use in outpatient and resource-limited clinical environments. This is a crucial consideration in global health terms. Fracture care and musculoskeletal disease impose an enormous burden in low- and middle-income countries, where access to advanced orthopedic technology is limited and where delayed unions and non-unions are more common because of delays in treatment. A device that can be built inexpensively, carried to a clinic, and configured by a clinician to match the patient’s condition could democratize access to regenerative ultrasound therapy in a way that commercial high-end systems have not. The investigators note that the device remains investigational and is not currently commercialized, and a patent related to the design has been issued to two of the authors, underscoring the translational intent behind the work.

Certain limitations frame the findings appropriately. The fracture evaluation was retrospective and controlled rather than randomized, and the tendinopathy component was exploratory without a comparison group, so the results should be read as strong feasibility and signal-generating evidence rather than definitive proof of efficacy. Nevertheless, the combination of a statistically significant acceleration in fracture healing, faster union probability confirmed by Kaplan-Meier analysis, favorable outcomes in difficult non-union cases, and an exceptionally high rate of clinically meaningful improvement in chronic tendinopathy makes a compelling case for larger, prospective, randomized trials. If those trials confirm these results, adaptive low-intensity pulsed ultrasound delivered by an affordable portable system could become a routine, accessible tool for accelerating fracture repair and managing stubborn tendon disorders, bringing a technology once confined to specialized centers within reach of patients everywhere.

Subject of Research: Adaptive low-intensity pulsed ultrasound therapy for accelerated fracture healing and chronic tendinopathic disorders

Article Title: Adaptive low-intensity pulsed ultrasound for accelerated fracture healing and chronic tendinopathic disorders: design and controlled clinical evaluation of a portable low-cost system

Article References: Shaheen, R., Mukhaiber, H., Naddaf, M., Alahmad, O. M., Sirees, S. K., & Ismaiel, E. (2026). Adaptive low-intensity pulsed ultrasound for accelerated fracture healing and chronic tendinopathic disorders: design and controlled clinical evaluation of a portable low-cost system. BioMedical Engineering OnLine. https://doi.org/10.1186/s12938-026-01617-3

Image Credits: AI Generated

DOI: 10.1186/s12938-026-01617-3

Keywords: low-intensity pulsed ultrasound, LIPUS, fracture healing, non-union, delayed union, bone regeneration, tendinopathy, biomedical engineering, portable medical device, non-invasive therapy, orthopedics, clinical evaluation